143 related articles for article (PubMed ID: 6435484)
1. Nitroglycerin concentration in plasma: comparison between transdermal therapeutic system and ointment.
Chu LC; Gale RM; Schmitt LG; Shaw JE
Angiology; 1984 Sep; 35(9):545-52. PubMed ID: 6435484
[TBL] [Abstract][Full Text] [Related]
2. Plasma nitroglycerin concentrations and hemodynamic effects of sublingual, ointment, and controlled-release forms of nitroglycerin.
Curry SH; Kwon HR; Perrin JH; Culp JR; Pepine CJ; Yu WC; Stevens JL
Clin Pharmacol Ther; 1984 Dec; 36(6):765-72. PubMed ID: 6437723
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-hemodynamic studies of transdermal nitroglycerin in congestive heart failure.
Armstrong PW
J Am Coll Cardiol; 1987 Feb; 9(2):420-5. PubMed ID: 3100600
[TBL] [Abstract][Full Text] [Related]
4. Plasma levels of nitroglycerin generated by three nitroglycerin patch preparations, Nitradisc, Transiderm-Nitro and Nitro-Dur and one ointment formulation, Nitrobid.
McAllister A; Mosberg H; Settlage JA; Steiner JA
Br J Clin Pharmacol; 1986 Apr; 21(4):365-9. PubMed ID: 3085698
[TBL] [Abstract][Full Text] [Related]
5. Studies of the bioavailability of nitroglycerin from a transdermal therapeutic system (Nitroderm TTS).
Imhof PR; Vuillemin T; Gérardin A; Racine A; Müller P; Follath F
Eur J Clin Pharmacol; 1984; 27(1):7-12. PubMed ID: 6436032
[TBL] [Abstract][Full Text] [Related]
6. Glycerol trinitrate (nitroglycerin) plasma concentrations achieved after application of transdermal therapeutic systems to healthy volunteers.
Gerardin A; Gaudry D; Moppert J; Theobald W; Fankhauser P
Arzneimittelforschung; 1985; 35(2):530-2. PubMed ID: 3922382
[TBL] [Abstract][Full Text] [Related]
7. Pharmaceutical considerations of transdermal nitroglycerin delivery: the various approaches.
Chien YW
Am Heart J; 1984 Jul; 108(1):207-16. PubMed ID: 6428207
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacokinetics and relative bioavailability of a nitroglycerin ointment formulation (author's transl)].
Maier-Lenz H; Ringwelski L; Windorfer A
Arzneimittelforschung; 1980; 30(2):320-4. PubMed ID: 6769443
[TBL] [Abstract][Full Text] [Related]
9. Performance of a new transdermal nitroglycerin adhesive patch formulation.
Riedel DJ; Wick KA; Hawkinson RW; Kolars CA; Crowley JK; Armstrong KE; Chang SF; Harrison LI; de Dennis SR
Clin Ther; 1989; 11(2):225-31. PubMed ID: 2500248
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the safety and efficacy of topical nitroglycerin ointment to facilitate venous cannulation.
Griffith P; James B; Cropp A
Nurs Res; 1994; 43(4):203-6. PubMed ID: 8047423
[TBL] [Abstract][Full Text] [Related]
11. Influence of the method of application on pharmacokinetics of nitroglycerin from ointment in humans.
Sved S; McLean WM; McGilveray IJ
J Pharm Sci; 1981 Dec; 70(12):1368-9. PubMed ID: 6798193
[TBL] [Abstract][Full Text] [Related]
12. Relative bioavailability of a new transdermal nitroglycerin delivery system.
Noonan PK; Gonzalez MA; Ruggirello D; Tomlinson J; Babcock-Atkinson E; Ray M; Golub A; Cohen A
J Pharm Sci; 1986 Jul; 75(7):688-91. PubMed ID: 3093667
[TBL] [Abstract][Full Text] [Related]
13. Effects of a transdermal patch system containing nitroglycerin on exercise tolerance in patients with angina pectoris. Double-blind, placebo controlled, comparison with slow-release nifedipine and verapamil.
Gibelli G; Negrini M; Mazzocchi F; Prina L; Pollavini P; De Ponti C
G Ital Cardiol; 1986 Nov; 16(11):904-8. PubMed ID: 3104124
[TBL] [Abstract][Full Text] [Related]
14. Absolute bioavailability of glyceryl trinitrate from a transdermal system, assessed by digital plethysmography.
Isenschmid M; Müller M; Bührer M; Vorkauf H; Bircher J
Int J Clin Pharmacol Ther Toxicol; 1985 Jul; 23(7):345-51. PubMed ID: 3928505
[TBL] [Abstract][Full Text] [Related]
15. Transdermal bioavailability and first-pass skin metabolism: a preliminary evaluation with nitroglycerin.
Nakashima E; Noonan PK; Benet LZ
J Pharmacokinet Biopharm; 1987 Aug; 15(4):423-37. PubMed ID: 3119815
[TBL] [Abstract][Full Text] [Related]
16. Nitroglycerin levels after administration via transdermal therapeutic system or as ointment.
Hirtz J; Imhof PR; Hauser PF
Lancet; 1984 Sep; 2(8403):633. PubMed ID: 6147658
[No Abstract] [Full Text] [Related]
17. Transdermal nitroglycerin ointment and patches.
Todd B
Geriatr Nurs; 1986; 7(3):152-4. PubMed ID: 3084347
[No Abstract] [Full Text] [Related]
18. Effect of dose and ointment application technique on nitroglycerin plasma concentrations.
Iafrate RP; Yost RL; Curry SH; Gotz VP; Caranasos GJ
Pharmacotherapy; 1983; 3(2 Pt 1):118-24. PubMed ID: 6406987
[TBL] [Abstract][Full Text] [Related]
19. Transdermal absorption of nitroglycerin from microseal drug delivery (MDD) system.
Karim A
Angiology; 1983 Jan; 34(1):11-22. PubMed ID: 6401951
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of nitroglycerin and clonidine delivered by the transdermal route.
Shaw JE
Am Heart J; 1984 Jul; 108(1):217-23. PubMed ID: 6428208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
